News Magenta Therapeutics

Stocks

MGTA

US55910K1088

Market Closed - Nasdaq 21:00:00 23/10/2026 BST			5-day change	1st Jan Change
76.78 ^USD	-2.23%		+6.51%	+585.93%

11/09/23	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
10/09/23	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

All News

Mentions Relevance

11/09/23	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
10/09/23	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI
07/08/23	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	BU
03/08/23	Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index	CI
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index	CI
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index	CI
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index	CI
19/05/23	Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer	CI
15/05/23	Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
04/05/23	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	BU
03/05/23	Dianthus Therapeutics, Inc., Magenta Therapeutics, Inc. - M&A Call
03/05/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
03/05/23	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement	AQ
02/05/23	Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.	CI
06/04/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement (form 8-K)	AQ
06/04/23	Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc	CI
31/03/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
31/03/23	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan	AQ
23/03/23	MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
28/02/23	HC Wainwright Initiates Magenta Therapeutics at Neutral	MT
07/02/23	MAGENTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers (form 8-K)	AQ
07/02/23	Magenta Therapeutics, Inc. Announces Management Changes	CI
07/02/23	Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive Officer	CI
02/02/23	MAGENTA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ